Kamel Ahmed Mohamed, Farag Mohamed Ali
Department of Clinical Pharmacy, and Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
J Med Food. 2022 Oct;25(10):931-942. doi: 10.1089/jmf.2022.0025. Epub 2022 Jun 28.
Nonalcoholic fatty liver disease (NAFLD) is a major chronic liver disease that can lead to liver cirrhosis, liver cancer, and death. Artichoke leaf extract (ALE) is well known in folk medicine for its hepatoprotective effect. Till recent times, no sufficient data from randomized clinical trials (RCTs) exist to support such use. This meta-analysis summarizes evidence from recent RCTs that evaluated ALE in NAFLD patients. Electronic databases were searched for RCTs that used ALE in NAFLD patients. The random-effects model was used to pool effect sizes (standardized change score). Data synthesis from five RCTs (333 patients) showed that ALE resulted in a significant reduction in alanine aminotransferase (standardized mean difference [SMD]: 1.1; 95% confidence interval [CI], 0.79-1.73; < .001) and aspartate aminotransferase levels (SMD: 1.01; 95% CI, 0.52-1.51; < .001) compared with the control group. ALE also resulted in a significant reduction in total cholesterol (SMD: 0.98; 95% CI, 0.53-1.43; = .004), low-density lipoprotein (SMD: 0.96; 95% CI, 0.3-1.62; < .001) and triglycerides (SMD: 0.95; 95% CI, 0.58-1.32; < .001). The current review provides evidence from RCTs to support the use of ALE as a hepatoprotective agent in NAFLD patients. The study was registered on the PROSPERO database with the Registration No. CRD42020182502 https://www.crd.york.ac.uk/prospero).
非酒精性脂肪性肝病（NAFLD）是一种主要的慢性肝病，可导致肝硬化、肝癌和死亡。洋蓟叶提取物（ALE）因其肝脏保护作用在民间医学中广为人知。直到最近，尚无来自随机临床试验（RCT）的充分数据支持这种用途。这项荟萃分析总结了近期评估NAFLD患者使用ALE的RCT证据。通过电子数据库搜索在NAFLD患者中使用ALE的RCT。采用随机效应模型汇总效应量（标准化变化分数）。来自五项RCT（333例患者）的数据合成表明，与对照组相比，ALE可显著降低丙氨酸氨基转移酶水平（标准化均数差[SMD]：1.1；95%置信区间[CI]，0.79 - 1.73；P <.001）和天冬氨酸氨基转移酶水平（SMD：1.01；95%CI，0.52 - 1.51；P <.001）。ALE还可显著降低总胆固醇（SMD：0.98；95%CI，0.53 - 1.43；P =.004）、低密度脂蛋白（SMD：0.96；95%CI，0.3 - 1.62；P <.001）和甘油三酯（SMD：0.95；95%CI，0.58 - 1.32；P <.001）。本综述提供了来自RCT的证据，支持在NAFLD患者中使用ALE作为肝脏保护剂。该研究已在PROSPERO数据库注册，注册号为CRD42020182502（https://www.crd.york.ac.uk/prospero）。
